Have any questions? 706-721-6582 or cts@augusta.edu
- M20-178: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
Clinical Trial
M20-178: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
This is a research study to test a new drug called Navitoclax that is not approved by the Food and Drug Administration (FDA) to treat relapsed/refractory myelofibrosis. We are looking to see if the drug works on your cancer, if the drug is safe and what type of treatment is better. This study has two different groups you can be assiged to: navitoclax + ruxolitinib or best available therapy. This assignment is done at random, as with the flip of a coin.
Eligibility Criteria
- Male or female, aged 18 years or older Subjects with confirmed relapsed/refractory myelofibrosis Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
RESEARCH. INNOVATION. DISCOVERY.